Drug Approval | July 09, 2024
Olverembatinib approved for commercialization in Macau China
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
The facility was inspected from May 7 to May 17, 2024
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
